Vergo Pharma Research Private Limited - Due diligence report

A 360° intelligence report on Vergo Clinicals: trust score, financial health, credit view, compliance, directors, growth and distress signal…

2010-09-23 Tiswadi, Goa Amalgamated Unlisted Active Compliant
Share
Connect MCP
VP Vergo Pharma Research Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Vergo Clinicals — 360° Intelligence Report

Generated from MCA filings & public records
52/100
Trust Score
Moderate

Vergo Clinicals is assessed as Moderate with a Trust Score of 52/100. Vergo Clinicals is a private limited indian non-government company incorporated in 2010, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 13 Aug 2026 from the latest processed filings. Vergo Pharma Research Private Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Neutral
Compliance › Caution

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
52/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
25/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
45/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (2.90 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Tata Capital Financial Services Limited1 48.0 cr
Compliance Score: 25/100 Caution Indicated
  • Company status is "Amalgamated" - not Active.
  • Balance sheet slightly behind (Mar 2024).
  • 2 auditor resignation(s) filed - latest: Dalvi Kamat Prabhudesai & Associates LLP on 2022-11-03.
  • Delayed payments to MSME suppliers disclosed (228 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
KASHYAP PRASAD KENI 01234567 Director 01/04/2018 6 yrs Approved
VINI PRASAD KENI 01234567 Director 01/04/2018 6 yrs Approved
PRASAD VASSUDEV KENI 01234567 Director 01/04/2018 6 yrs Approved
PRAVEEN KHULLAR 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Vergo Pharma Research Laboratories Private Limited
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Vergo Pharma Research Laboratories Private Limited Holding Company 74.00%

Key managerial personnel: PRASAD VASSUDEV KENI (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 30
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 15+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Negative net worth.
Adverse company status: Amalgamated.
Compliance score is weak (25/100).
1 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 1.26 cr.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence35/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment51/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 2.90 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view59/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
20 Sep 2024
Last AGM held
Annual general meeting
19 Sep 2024
Director ceased
PRAVEEN KHULLAR
23 Jul 2024
Director appointed
PRAVEEN KHULLAR (Director)
31 Mar 2024
Latest balance sheet
Filed with ROC
29 Nov 2022
Charge created
Tata Capital Financial Services Limited - 2.90 cr
30 Sep 2022
Director ceased
AMOL SHIVAJI BORKAR
28 Sep 2019
Director ceased
KASHYAP PRASAD KENI
19 Sep 2019
Director appointed
KASHYAP PRASAD KENI (Director)
10 Sep 2019
Director ceased
GAJANAN JAIVANT SURLAKAR
31 Mar 2018
Share transfer (FY 2018)
500.00000000 shares to PRIVATE LIMITED RESEARCH LABORATORIES VERGO PHARMA
Share transfer (FY 2018)
1.00000000 shares to RESEARCH LABORATORIES PVT. LTD. JOINTLY WITH VERGO PHARMA GAJANAN SURLAKAR
24 Jun 2016
Director ceased
SULBA VENCTEXA SURLACAR
01 Sep 2013
Director ceased
PRASAD VASSUDEV KENI
23 Sep 2010
Incorporated
Registered with Roc Goa
Director appointed
VINI PRASAD KENI (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Apnarpharma U73100GJ2014PTC081520 Padra, Gujarat, India
Skyroot Aerospace U74999TG2018PTC125073 Hyderabad, Telangana, India
Amura Marketing Technologies U72200PN2010PTC135364 Pune, Maharashtra, India
A2Mac1 India Private Limited U74900TN2016PTC104128 Walajabad Taluk, Tamil Nadu, India
Botlab Dynamics U35990DL2016PTC447470 New Delhi, Delhi, India
Difgen Pharmaceuticals Private Limited U72100TG2022PTC162383 Balanagar, Telangana, India
Solistaa Pharmaceuticals Private Limited U24304PY2017PTC008222 Pondicherry, Pondicherry, India
Aus U35122KA2013PTC141030 Jakkur, Karnataka, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Vergo Clinicals before audits and certifications: compliance score 25/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Vergo Clinicals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Vergo Clinicals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 52/100, distress signals and MSME payment-delay disclosures - know whether Vergo Clinicals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Vergo Clinicals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Vergo Clinicals an active company?

Vergo Clinicals has MCA status “Amalgamated” with a compliance score of 25/100 (Caution Indicated).

Is Vergo Clinicals financially healthy?

Vergo Clinicals has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Vergo Clinicals?

Its overall Trust Score is 52/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Vergo Clinicals?

The ultimate holding entity is Vergo Pharma Research Laboratories Private Limited. 4 active director(s) are on record.

Does Vergo Clinicals have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Vergo Clinicals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 25/100 (Caution Indicated).

Is it risky to lend to Vergo Clinicals?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.